Pyxis Oncology, Inc. Earnings Per Share, Basic and Diluted
Pyxis Oncology, Inc. (PYXS) reported Earnings Per Share, Basic and Diluted of -$0.97 per share for the 3-month period ending 2022-03-31, per its 10-Q filed 2022-05-13.
Discontinued › Income Statement › Earnings Per Share
us-gaap:EarningsPerShareBasicAndDiluted · last filed 2022-05-13
- Pyxis Oncology, Inc. earnings per share, basic and diluted for the quarter ending 2022-03-31 was -$0.97.
- Pyxis Oncology, Inc. earnings per share, basic and diluted for the quarter ending 2021-12-31 was -$0.57.
- Pyxis Oncology, Inc. earnings per share, basic and diluted for the quarter ending 2021-09-30 was -$8.96.
- Pyxis Oncology, Inc. earnings per share, basic and diluted for the quarter ending 2021-03-31 was -$27.26.
- Pyxis Oncology, Inc. earnings per share, basic and diluted for fiscal 2021 was -$8.95.
- Pyxis Oncology, Inc. earnings per share, basic and diluted for fiscal 2020 was -$12.45.
| Period end | Earnings Per Share, Basic and Diluted 3 month | Earnings Per Share, Basic and Diluted 6 month | Earnings Per Share, Basic and Diluted 9 month | Earnings Per Share, Basic and Diluted 12 month |
|---|---|---|---|---|
| 2022-03-31 | -$0.97 10-Q · filed 2022-05-13 | -$1.56 derived: net income ÷ weighted average shares · filed 2023-08-11 | -$2.95 derived: net income ÷ weighted average shares · filed 2023-08-11 | |
| 2021-12-31 | -$0.57 derived: net income ÷ weighted average shares · filed 2023-03-22 | -$1.99 derived: net income ÷ weighted average shares · filed 2023-03-22 | -$8.95 10-K · filed 2022-03-29 | |
| 2021-09-30 | -$8.96 10-Q · filed 2021-11-15 | -$40.27 10-Q · filed 2021-11-15 | ||
| 2021-03-31 | -$27.26 10-Q · filed 2022-05-13 | -$32.66 derived: net income ÷ weighted average shares · filed 2022-08-15 | -$36.92 derived: net income ÷ weighted average shares · filed 2022-08-15 | |
| 2020-12-31 | -$3.86 derived: net income ÷ weighted average shares · filed 2022-03-29 | -$6.84 derived: net income ÷ weighted average shares · filed 2022-03-29 | -$12.45 10-K · filed 2022-03-29 | |
| 2020-09-30 | -$2.93 10-Q · filed 2021-11-15 | -$8.43 10-Q · filed 2021-11-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Akebia Therapeutics, Inc. (AKBA) | United States | $0.255B | -10.35 |
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |